EMA Panexcell Review Leads Tillomed To Pull Doxorubicin
Follows Major GCP Issues Identified At CRO Panexcell’s Site
Emcure’s Tillomed has been forced to withdraw its application for a version of doxorubicin, in light of the EMA taking a closer look at medicines for which study data prepared by Panexcell Clinical Laboratories was used to support marketing authorization applications.
